Upregulation of the HOXA10-AS1 LncRNA in Gastric Cancer: An Expression and Bioinformatics Analysis

TL;DR

This study finds that the HOXA10-AS1 long non-coding RNA is overactive in gastric cancer tissues and could help diagnose the disease.

Contribution

The study identifies HOXA10-AS1 as a potential diagnostic biomarker for gastric cancer through its upregulated expression.

Findings

HOXA10-AS1 is significantly upregulated in gastric cancer tissues compared to non-cancerous tissues.

The diagnostic power of HOXA10-AS1 is moderate with an AUC of 0.64 in distinguishing tumor from normal tissues.

Abstract

Gastric cancer (GC) is a lethal disease with poor prognosis. Long non-coding RNAs (lncRNAs) involved in the development of cancer through changes in their expression levels. In present study, we aimed to evaluate HOXA10-AS gene expression and its potential as a biomarker in GC.

In this study 60 subjects (30 gastric carcinoma tissues and 30 adjacent non-carcinoma tissues) were examined. The expression level of the HOXA10-AS gene was evaluated using quantitative PCR. Furthermore, clinicopathological characteristicswere taken into consideration. Diagnostic value of the HOXA10-AS was examined by ROC curve analysis. Bioinformatics analysis was performed using different databases.

Expression of HOXA10-AS was significantly upregulated in GC tumoral tissues. Roc curve analysis revealed that the diagnostic power of HOXA10-AS was high (AUC = 0.64) in the tumor compared to the normal GC tissues.

Our findings show that HOXA10-AS expression level is higher in the GC tumor compared to the adjacent non-carcinoma tissues and can act as a strong diagnostic biomarker in GC patients.

Figures